antibody-modified nanomaterials frequently suffer from low drug loading and loss of function of antibodies due to the covalent modification of antibodies. For instance, less than five drug molecules can be conjugated to an antibody in an ADC molecule. Otherwise, the resulting ADC molecule may lose its affinity to the target, or it may aggregate into precipitates, especially for hydrophobic drug-modified antibody molecules. Developing antibody-based nanomedicines with high drug loading, high specificity to tumors, and a versatile preparation procedure remains challenging. In this study, we demonstrated that enzyme-instructed self-assembly (EISA) [2] was a versatile process to prepare coassembled supramolecular nanofibers of drug-peptide amphiphiles and an affibody (antiHER2), which abolished HER2+ tumor growth in vivo.Recently, drug-peptide amphiphiles emerged as promising prodrugs to construct nanomedicines with high and designable drug loading, enhanced stability and selectivity, constant and sustained release properties, etc. [3] However, the selectivity of these nanomedicines to tumors relies on the enhanced permeation and retention effect, which is relatively low compared with antibody-based nanomedicines. We recently demonstrated that self-assembling peptides could form coassembled nanofibers with proteins during the selfassembly process, and the resulting coassembled nanofibers and hydrogels were very useful for protein/antigen delivery. [4] These results encouraged us to combine the advantages of both drug-peptide amphiphiles and antibodies to prepare coassembled nanofibers of self-assembling peptides and antibodies with high specificity and high affinity for cancer therapy (Figure 1).
Results and Discussion
Design of Affibody and Peptide Amphiphile for the Preparation of Coassembled Supramolecular NanofibersHuman epidermal growth factor receptor 2 (HER2) is a validated therapeutic target for breast and gastric cancers, and the overexpression of HER2 is associated with an unfavorable prognosis. [5] We first prepared an HER2-specific affibody molecule (ZHER2:2891, antiHER2), a 58-amino acid peptide engineered from the Z domain the skeleton of staphylococcal protein Antibody-based medicines and nanomedicines are very promising for cancer therapy due to the high specificity and efficacy of antibodies. However, antibody-drug conjugates and antibody-modified nanomaterials frequently suffer from low drug loading and loss of functions due to the covalent modification of the antibody. A novel and versatile strategy to prepare supramolecular nanomaterials by the coassembly of an affibody (antiHER2) and drug-peptide amphiphiles is reported here. During the enzyme-instructed self-assembly process, the drug-peptide amphiphile can coassemble with the affibody, resulting in supramolecular nanofibers in hydrogels. The drug loading in the supramolecular nanofibers is high (>30 wt%), and the stability of antiHER2 is significantly improved in the nanofibers at 37 °C (>15 d in vitro). The supramolecular nanofibers exhib...